- Belzutifan approved for adult and pediatric patients with certain tumors
- Demonstrated reduction in tumor size and antihypertensive medication use
- Common adverse reactions include anemia, fatigue, and musculoskeletal pain
- Recommended adult dose: 120 mg orally once daily
- Pediatric dosing based on body weight
Source: FDA
